Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 05, 2015 7:02 PM ET

Healthcare Providers and Services

Company Overview of Ranbaxy Pharmaceuticals, Inc.

Company Overview

Ranbaxy Pharmaceuticals, Inc. markets prescription and generic pharmaceutical products in the United States. Its product line includes anti-infective, cardiovascular, non-steroidal anti-inflammatory, anti-expectorant, analgesic, gastrointestinal, and central nervous system products, as well as controlled substances. The company was incorporated in 2004 and is based in Princeton, New Jersey. Ranbaxy Pharmaceuticals, Inc. is a subsidiary of Ranbaxy Inc.

600 College Road East

Suite 2100

Princeton, NJ 08540

United States

Founded in 2004

Phone:

609-720-9200

Fax:

609-720-1155

Key Executives for Ranbaxy Pharmaceuticals, Inc.

Head of Finance and Director
Chief Executive Officer of Ramnaxy and Managing Director of Ranbaxy
Age: 59
Vice President of Corporate Communications and Vice President of Government Affairs
Executive Director of Medical and Clinical Affairs
Senior Vice President, Regional Director of Americas and Director
Compensation as of Fiscal Year 2014.

Ranbaxy Pharmaceuticals, Inc. Key Developments

Attorney General Eric T. Schneiderman Announces Settlement with Ranbaxy Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc for Entering into Anticompetitive Arrangement

Attorney General Eric T. Schneiderman announced a settlement with two generic pharmaceutical manufacturers, Ranbaxy Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc., resolving concerns that an agreement between them unlawfully restricted competition. The collusive agreement, under which each of the generic drug companies committed not to challenge certain regulatory exclusivities held by the other, served to protect each party's market positions with respect to dozens of drugs, and reduced the risk that each would face greater competition for its generic drugs. The settlement requires the companies to terminate their unlawful agreement, commit not to enter into similar agreements in the future, and make a monetary payment to the State. The case also represents the latest application of recent legal precedent arising out of challenges to pay for delay agreements between brand name and generic pharmaceutical manufacturers. The agreement between Ranbaxy and Teva relates to a type of regulatory exclusivity awarded to the first manufacturer that seeks to market a generic version of a brand manufacturer's drug prior to expiration of the brand manufacturer's patents.

Similar Private Companies By Industry

Company Name Region
Sibley Medical Center United States
Gulf Coast Regional Blood Center United States
Dekalb Regional Healthcare System Inc. United States
Cedar Springs Hospital, Inc. United States
AmCare Health Plans of Louisiana Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ranbaxy Pharmaceuticals, Inc., please visit www.ranbaxy.com/us. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.